Biologics contract development and manufacturing organization (CDMO), iBiO Inc. (NYSEAMERICAN:IBIO) has announced the signing of its first Statement of Work under a Master Services Agreement with ATB Therapeutics.
atbtherapeutics to leverage iBio’s FastPharming® in the development of atbodies
The agreement will see atbtherapeutics leverage iBio’s FastPharming® System to manufacture its bioengineered antibody-toxin fusion proteins (atbodies). The FastPharming® System employs vertical farming, glycan engineering, and automated hydroponics technologies for rapid delivery of high-quality monoclonal antibodies, bioinks, and vaccines, as well as other proteins. iBio’s subsidiary iBio CDMO LLC will provide atbtherapeutics with the FastPharming contract development and manufacturing services to produce atbodies.
Atbtherapeutics has designed atbodies for the treatment of cancer. It is a novel biologic differentiated by an exceptional composition and proprietary action mechanism. The atbodies aim at extending the therapeutic window of existing targeted therapies. The novel therapeutic is only achievable through atbtherapeutics’ plant-based atbiofarm technology. The company is currently advancing its first hematological malignancies program and a second solid tumors program in its proprietary portfolio.
iBio to develop manufacturing and process assays for atbodies
According to the Statement of Work, iBio will develop manufacturing processes and assays for specific atbodies. Tom Isett, iBio’s CEO and Chairman, stated that they are delighted to sign a partnership with atbtherapeutics for process development and manufacturing of atbodies. He said that atbtherapeutics’ platform tech provides an exceptional approach for hard-to-treat solid tumors and hematological malignancies. Isett said that they are looking forward to assisting atbtherapeutics in creating a scalable manufacturing process quickly. This will enable its atbody drug candidates to reach the clinic fast and realize their oncology potential.
Atbtheraputics CEO Bertrand Magy stated that they are delighted to partner with a premium, customer-focused CDMO such as iBio. Bertrand said that iBio has proven expertise that will be vital for the company to develop atbodies ahead of atbtherapeutics’ first safety trials. He said that with support from iBio, they are optimistic that they will rapidly progress towards clinical studies with their lead drug candidates for cancer treatment.